Effects of systemic administration of Hesa-A on the expression of Cycline D1 , EGFR and Cadherin in the induced tongue dysplasia in rats

Abstract

Introduction: HESA-A® has herbal and marine bases containing minerals and rare compounds such as Zr, Cr, Ga, Mn, Mg, Ca, Sr, Cu, Ti and others. Its mechanism of action includes antioxidant, anti-inflammatory and adjustment of immune system. The aim of this study was evaluation the effects of HESA-A® systemic drug on expression of Cyclin D1, EGFR and E-Cadherin in rats' induced tongue dysplasia. Methods: In this laboratory study, the effects of the systemic drug HESA-A on the expression of Cyclin D1, EGFR, and E-Cadherin molecular markers in rats' induced tongue dysplasia were examined. Results: Expression of Cyclin D1 in groups receiving HESA-A® was lower than the group that did not receive the drug (77.78% in the 0-5% range versus 77.78% in the 5-50% range). In the case of expression of E-Cadherin in group D, which did not receive HESA-A®, a decrease was observed in expression of this cell adhesion marker as compared to the other two groups. The expression of E-Cadherin was dependent on HESA-A® dose, while with 500 mg/kg it was higher than other groups (Over 75% in 55.55% versus over 75% in 11.11%).Concerning incidence of EGFR in all three groups most cases were Grade 0. Conclusion: Results of the present research indicate that considering changes in expression of Cyclin D1 and E-Cadherin markers in groups treated with HESAA®, HESA-A® has preventive effects on development of cancer in dysplastic lesions through regulation of expression of these molecules.